These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21710803)

  • 41. [Use of 17-alpha-hydroxprogesterone-capronate in certain malignant tumors].
    Garin AM; Voznyĭ EK; Borisov VI; Dobrushina VA; Lazovskaia EB
    Klin Med (Mosk); 1974 Mar; 52(3):121-3. PubMed ID: 4466932
    [No Abstract]   [Full Text] [Related]  

  • 42. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F; Vaccaro V
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 46. Support system: through charities, drug makers help people--and themselves.
    Anand G
    Wall St J (East Ed); 2005 Dec; ():A1, A10. PubMed ID: 16502554
    [No Abstract]   [Full Text] [Related]  

  • 47. [Are gestagens suitable for lowering the membrane potential of the uterine muscle and eliminating the need for beta-mimetics?].
    Spätling L
    Gynakologe; 1992 Jun; 25(3):201. PubMed ID: 1354628
    [No Abstract]   [Full Text] [Related]  

  • 48. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Regularities and paradoxes of endocrine dependence and hormonal therapy of endometrial cancer].
    Bokhman IaV; Volkova AT; Chepik OF; Vishnevskiĭ AS
    Vopr Onkol; 1990; 36(11):1382-8. PubMed ID: 2281650
    [No Abstract]   [Full Text] [Related]  

  • 50. Orphan drugs: the question of products liability.
    Scharf SF
    Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 52. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 54. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

  • 55. The National Cancer Institute's Drug Development Program.
    Schepartz SA
    Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
    [No Abstract]   [Full Text] [Related]  

  • 56. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS; Brent RL; Calda P
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 58. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
    Combs CA; Garite T; Maurel K; Das A; Porto M;
    Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
    Grienenberger A
    J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.